For research use only. Not for therapeutic Use.
NYX-2925 is an orally active NMDAR modulator. NYX-2925 restores levels of activated Src and Src phosphorylation sites on GluN2A and GluN2B in the mPFC. NYX-2925 shows no effect on CAMKII, and any addictive or sedative/ataxic side effects. NYX-2925 can be used for research of a variety of NMDA receptor-mediated central nervous system disorders[1][2].
| Catalog Number | I041317 |
| CAS Number | 2012536-16-0 |
| Synonyms | (2S,3R)-3-hydroxy-2-[(4R)-5-(2-methylpropanoyl)-3-oxo-2,5-diazaspiro[3.4]octan-2-yl]butanamide |
| Molecular Formula | C14H23N3O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C14H23N3O4/c1-8(2)12(20)17-6-4-5-14(17)7-16(13(14)21)10(9(3)18)11(15)19/h8-10,18H,4-7H2,1-3H3,(H2,15,19)/t9-,10+,14-/m1/s1 |
| InChIKey | NFXPEHLDVKVVKA-ISTVAULSSA-N |
| SMILES | CC(C)C(=O)N1CCCC12CN(C2=O)C(C(C)O)C(=O)N |
| Reference | [1]. Morrison G, et al. The NMDAR modulator NYX-2925 alleviates neuropathic pain via a Src-dependent mechanism in the mPFC. Neurobiol Pain. 2019 Dec 4;7:100039. [2]. Khan MA, et al. NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory. Int J Neuropsychopharmacol. 2018 Mar 1;21(3):242-254. |
